Tags

Type your tag names separated by a space and hit enter

Patients benefit from genetics-guided coumarin anticoagulant therapy.
Clin Pharmacol Ther. 2014 Jul; 96(1):15-7.CP

Abstract

Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings.

Authors+Show Affiliations

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.Institute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, UK.Institute of Cellular Medicine, Newcastle University Medical School, Newcastle upon Tyne, UK.No affiliation info availableLaboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden.Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.The Wolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.No affiliation info available

Pub Type(s)

Journal Article
Comment

Language

eng

PubMed ID

24942396

Citation

Maitland-van der Zee, A H., et al. "Patients Benefit From Genetics-guided Coumarin Anticoagulant Therapy." Clinical Pharmacology and Therapeutics, vol. 96, no. 1, 2014, pp. 15-7.
Maitland-van der Zee AH, Daly AK, Kamali F, et al. Patients benefit from genetics-guided coumarin anticoagulant therapy. Clin Pharmacol Ther. 2014;96(1):15-7.
Maitland-van der Zee, A. H., Daly, A. K., Kamali, F., Manolopoulous, V. G., Manolopoulos, V. G., Verhoef, T. I., Wadelius, M., de Boer, A., & Pirmohamed, M. (2014). Patients benefit from genetics-guided coumarin anticoagulant therapy. Clinical Pharmacology and Therapeutics, 96(1), 15-7. https://doi.org/10.1038/clpt.2014.44
Maitland-van der Zee AH, et al. Patients Benefit From Genetics-guided Coumarin Anticoagulant Therapy. Clin Pharmacol Ther. 2014;96(1):15-7. PubMed PMID: 24942396.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patients benefit from genetics-guided coumarin anticoagulant therapy. AU - Maitland-van der Zee,A H, AU - Daly,A K, AU - Kamali,F, AU - Manolopoulous,V G, AU - Manolopoulos,V G, AU - Verhoef,T I, AU - Wadelius,M, AU - de Boer,A, AU - Pirmohamed,M, AU - ,, PY - 2014/6/20/entrez PY - 2014/6/20/pubmed PY - 2014/8/5/medline SP - 15 EP - 7 JF - Clinical pharmacology and therapeutics JO - Clin. Pharmacol. Ther. VL - 96 IS - 1 N2 - Observational studies have overwhelmingly shown that variants in the genes CYP2C9 and VKORC1 are significant determinants of individual dose of coumarin anticoagulants needed to maintain a therapeutic international normalized ratio (INR).(1) Until recently, however, few randomized clinical trials had been performed relating to the use of genetic data to predict dosing. Three sucsh clinical trials have now reported their findings. SN - 1532-6535 UR - https://www.unboundmedicine.com/medline/citation/24942396/Patients_benefit_from_genetics_guided_coumarin_anticoagulant_therapy_ L2 - https://doi.org/10.1038/clpt.2014.44 DB - PRIME DP - Unbound Medicine ER -